Key result
Enalapril treatment (30 mg/kg for 5 weeks) attenuated vascular hypertrophy, extracellular matrix protein increases, and blood-brain barrier breakdown in rats with chronic renal hypertension.
Why the study?
Does enalapril attenuate cerebrovascular changes and blood-brain barrier breakdown in rats with chronic renal hypertension?
Population
Rats with surgically induced chronic renal hypertension
Comparison
Enalapril (30 mg/kg) orally for 5 weeks vs Untreated hypertensive rats
Design
Preclinical
Follow-up
5 weeks
Authors
Loading...
Supports preclinical testing of ACE inhibition for cerebrovascular protection; leaves open translation to human chronic hypertension.
Does enalapril attenuate cerebrovascular changes and blood-brain barrier breakdown in rats with chronic renal hypertension?
Enalapril attenuates vascular hypertrophy, extracellular matrix protein increases, and blood-brain barrier breakdown in a rat model of chronic hypertension.
Nag et al. (1997) studied Chronic renal hypertension. Enalapril vs. Untreated hypertensive rats was evaluated on Vascular hypertrophy, vascular extracellular matrix proteins, and blood-brain barrier permeability. Enalapril treatment (30 mg/kg for 5 weeks) attenuated vascular hypertrophy, extracellular matrix protein increases, and blood-brain barrier breakdown in rats with chronic renal hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: